Bioharvest Sciences Inc.
BHST Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- Bioharvest Sciences Inc. had $34.5M of revenue in fiscal 2025, up 37.0% on the year before.
- Its operating margin was −16.2%, up 11.6 pts: of every 100 in sales, about −16 is left after running the business.
- Bioharvest Sciences Inc. lost $11.1M in fiscal 2025.
- Free cash flow was −$9.6M in fiscal 2025, −27.8% of revenue.
- Bioharvest Sciences Inc. has $22.9M more cash than debt.
Market cap
—
P/E
—
Revenue
$34.5M
Net income
−$11.1M
Free cash flow
−$9.6M
Operating margin
−16.2%
Bioharvest Sciences Inc. in 30 seconds · fiscal 2025
Are sales growing?
+37.0%
Yes. Sales grew 37.0% last year.
Does it make a profit?
−32.3%
No. It lost money last year.
Does profit turn into cash?
−27.8%
No. It spent more cash than it brought in.
What Bioharvest Sciences Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 40-F · Mar 31, 2026
- Legal name
- BIOHARVEST SCIENCES INC.
- CIK
- 0001723464
Bioharvest Sciences Inc. · BHST
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $12.7M | $25.2M | $34.5M |
| Revenue growth | — | 98.8% | 37.0% |
| Gross margin | 44.5% | 55.4% | 59.3% |
| Operating margin | −78.6% | −27.7% | −16.2% |
| Net income | −$12.6M | −$12.9M | −$11.1M |
| Net margin | −99.1% | −51.3% | −32.3% |
| Cash | |||
| Cash from operations | −$8.5M | −$6.7M | −$7.2M |
| Capital expenditure | $1.5M | $2.8M | $2.4M |
| Free cash flow | −$10.0M | −$9.5M | −$9.6M |
| FCF margin | −78.9% | −37.8% | −27.8% |
| Debt and strength | |||
| Cash and short-term investments | $5.4M | $2.4M | $23.0M |
| Debt incl. finance leases | $0.0M | $3.9M | $0.1M |
| Shareholders' equity | −$14.9M | $1.3M | $25.4M |
| Current ratio | 0.3x | 0.6x | 4.0x |
| Returns and quality | |||
| Return on capital | — | −194.1% | −171.2% |
| Return on equity | — | — | −83.2% |
| Return on tangible equity | — | −970.9% | −43.8% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bioharvest Sciences Inc. · BHST
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001723464). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.